|
|
|
|
|||||
|
|
|
SAN DIEGO, July 23, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that the executive management team will be participating in the BTIG Virtual Biotechnology Conference being held July 29-30, 2025.
To schedule a one-on-one meeting with management, please reach out to your BTIG representative.
About Belite Bio
Belite Bio is a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, such as Stargardt disease type 1 (STGD1) and Geographic Atrophy (GA) in advanced dry age-related macular degeneration (AMD), in addition to specific metabolic diseases. Belite’s lead candidate, Tinlarebant, an oral therapy intended to reduce the accumulation of toxins in the eye, is currently being evaluated in a Phase 3 study (DRAGON) and a Phase 2/3 study (DRAGON II) in adolescent STGD1 subjects and a Phase 3 study (PHOENIX) in subjects with GA. For more information, follow us on X, Instagram, LinkedIn, and Facebook or visit us at www.belitebio.com.
Media and Investor Relations Contact:
Jennifer Wu
[email protected]
Julie Fallon
[email protected]
| Aug-27 | |
| Aug-12 | |
| Aug-11 | |
| Aug-07 | |
| Aug-06 | |
| Aug-04 | |
| Aug-04 | |
| Jul-23 | |
| Jul-22 | |
| Jul-03 |
Enrolment concludes in Belite Bios trial of Tinlarebant for geographic atrophy
BLTE
Clinical Trials Arena
|
| Jul-02 | |
| May-21 | |
| May-16 | |
| May-15 | |
| May-13 |
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite